Dr. Reddy's Laboratories Ltd. (RDY)

35.24
0.35 1.00
NYSE : Health Technology
Prev Close 34.89
Open 34.98
Day Low/High 34.96 / 35.50
52 Wk Low/High 31.58 / 42.82
Volume 164.31K
Avg Volume 183.80K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 5.85B
EPS 1.60
P/E Ratio 21.27
Div & Yield 0.26 (0.82%)
Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

The ex-dividend date for Dr. Reddy Laboratories (NYSE:RDY) is tomorrow, June 27, 2012. Owners of shares as of market close today will be eligible for a dividend of 21 cents per share. At a price of $28 as of 10:05 a.m., the dividend yield is 0.8%.

Dr. Reddy’s Announces The Launch Of Ropinirole Hydrochloride XR (Extended-Release) Tablets

Dr. Reddy’s Announces The Launch Of Ropinirole Hydrochloride XR (Extended-Release) Tablets

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has launched Ropinirole Hydrochloride XR (Extended-Release) tablets (2 mg, 4 mg, 6 mg, 8mg, and 12 mg), a bioequivalent generic version of REQUIP XL ®...

Dr. Reddy’s Announces The Launch Of Over-the-Counter Lansoprazole Delayed-Release Capsules

Dr. Reddy’s Announces The Launch Of Over-the-Counter Lansoprazole Delayed-Release Capsules

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched over-the-counter (OTC) Lansoprazole delayed-release capsules in the U.

Dr. Reddy’s Announces The Launch Of Clopidogrel Tablets, USP

Dr. Reddy’s Announces The Launch Of Clopidogrel Tablets, USP

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX ®, in the U.

Dr. Reddy's Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript

Dr. Reddy's To Release Q4 & Full Year FY12 Results On May 11, 2012

Dr. Reddy's To Release Q4 & Full Year FY12 Results On May 11, 2012

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter & Full Year ended March 31, 2012 on Friday, May 11, 2012 after the Board Meeting.

Dr. Reddy’s Announces The Launch Of Quetiapine Fumarate Tablets

Dr. Reddy’s Announces The Launch Of Quetiapine Fumarate Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Quetiapine fumarate tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg), a bioequivalent generic version of SEROQUEL ® tablets...

Dr. Reddy’s Announces The Launch Of Ziprasidone Hydrochloride Capsules

Dr. Reddy’s Announces The Launch Of Ziprasidone Hydrochloride Capsules

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Ziprasidone Hydrochloride Capsules, a bioequivalent generic version of Geodon ® in the US market on March 2, 2012 following the...

Dr. Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript

Dr. Reddy’s Q3 FY12 Financial Results

Dr. Reddy’s Q3 FY12 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's To Release Q3 FY12 Results On February 3, 2012

Dr. Reddy's To Release Q3 FY12 Results On February 3, 2012

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended and Nine Months ended December 31, 2011 on Friday February 3, 2012 after the Board Meeting.

Generics Could Be Exceptional

The generic drug market looks strong over the long term and should continue to perform well in the future.

Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States

Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Dr.

Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States

Teva And Dr. Reddy’s Announce Launch Of Generic Zyprexa® In The United States

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Dr.

Dr. Reddy’s Q2 FY12 Financial Results

Dr. Reddy’s Q2 FY12 Financial Results

Dr. Reddy’s Laboratories Ltd.

6 Best-Performing Emerging Market ADRs

6 Best-Performing Emerging Market ADRs

These six emerging-market stocks piled on significant gains in the past month, outperforming their respective domestic markets and the S&P index.

Dr. Reddy’s Announces The Launch Of Rivastigmine Tartrate Capsules

Dr. Reddy’s Announces The Launch Of Rivastigmine Tartrate Capsules

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Rivastigmine Tartrate Capsules (1.

Dr. Reddy’s Announces Start Of Phase II Study With The CETP Inhibitor, DRL-17822 In Dyslipidemia Patients

Dr. Reddy’s Announces Start Of Phase II Study With The CETP Inhibitor, DRL-17822 In Dyslipidemia Patients

Dr. Reddy’s Laboratories (NYSE: RDY) announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia.

Dr. Reddy’s Announces Settlement Of Lipitor® (atorvastatin) ANDA Litigation With Pfizer

Dr. Reddy’s Announces Settlement Of Lipitor® (atorvastatin) ANDA Litigation With Pfizer

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has entered into a settlement agreement with Pfizer which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known ...

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl And Pseudoephedrine HCl Extended Release Tablets

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl And Pseudoephedrine HCl Extended Release Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine HCl and Pseudoephedrine HCl extended release tablets 180 /240 mg.

8 New ETF Gems to Trade

8 New ETF Gems to Trade

Month after month, brand new exchange-traded funds are introduced to the market. Take a look at the recent offerings that offer pure-play exposure to individual emerging market sectors.

5 Winners in Emerging Markets ADRs

5 Winners in Emerging Markets ADRs

While the markets were sliding this week, a handful of emerging markets stocks were turning in gains.

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM Corporation (Head office: Tokyo, Japan) President and CEO, Shigetaka Komori (“Fujifilm” hereinafter) and Dr.

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM And Dr. Reddy’s To Establish An Exclusive Joint Venture For Developing, Manufacturing And Promoting Generic Drugs In Japan

FUJIFILM Corporation (Head office: Tokyo, Japan) President and CEO, Shigetaka Komori (“Fujifilm” hereinafter) and Dr.

Dr. Reddy’s Announces The Launch Of Gemcitabine For Injection

Dr. Reddy’s Announces The Launch Of Gemcitabine For Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar ®* in the US market on July 25,...

Dr. Reddy’s Acquires Prescription Business Of JB Chemicals & Pharmaceuticals In Russia & Other CIS Markets

Dr. Reddy’s Acquires Prescription Business Of JB Chemicals & Pharmaceuticals In Russia & Other CIS Markets

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has entered into an agreement with JB Chemicals & Pharmaceuticals to acquire their pharmaceutical prescription portfolio in the Russia and other CIS ...

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dr. Reddy's Q1 FY12 Financial Results

Dr. Reddy's Q1 FY12 Financial Results

Dr. Reddy’s Laboratories Ltd.

TheStreet Quant Rating: B- (Buy)